Upcoming IPO: Sai Life Sciences Fixes Price Band, Public Issue To Open On December 11; Key Details Here

Hyderabad-based Sai Life Sciences Ltd is gearing up for its initial public offering (IPO), which is set to open for subscription on December 11, 2024. The company has announced a price band of Rs 522-549 per share for the offering, which comprises a fresh issue of Rs 950 crore and an offer for sale (OFS) of up to 38.12 million shares by existing shareholders and promoters. At the upper price band, the OFS size will total Rs 2,092.79 crore, making the overall issue size approximately Rs 3,042.79 crore. Post-listing, Sai Life Sciences is expected to command a market capitalization of around Rs 11,400 crore.

Key Dates

The IPO's anchor bidding process will begin on December 10 and end on December 13. Allotment of shares is scheduled for December 16, with refunds to be issued on December 17. The company's shares will make their debut on stock exchanges on December 18, adding to the pipeline of IPOs in 2024.

A portion of the proceeds from the fresh issue, amounting to Rs 720 crore, is earmarked for debt repayment. As of September 2024, Sai Life Sciences' total debt stood at Rs 764.49 crore. The IPO is expected to provide a financial boost to the company, enabling it to enhance its balance sheet and support its growth initiatives.

Stakeholders

TPC Capital, which invested $135 million in Sai Life Sciences in 2018 and currently holds a 38.83% stake in the company, plans to exit through this public listing. The IPO is being managed by a consortium of leading investment banks, including Kotak Mahindra Capital, IIFL Capital, Jefferies India, and Morgan Stanley.

About Sai Life Sciences

Sai Life Sciences operates as a contract research, development, and manufacturing organization (CRDMO) that provides end-to-end services for small molecule new chemical entities. With a focus on innovation, the company supports global pharmaceutical and biotech innovators through integrated discovery, CMC (Chemistry, Manufacturing, and Controls), and CDMO (Contract Development and Manufacturing Organization) capabilities.

Financial Performance

The financial performance of Sai Life Sciences has shown marked improvement in recent months. For the six months ending September 2024, the company reported a total income of Rs 693.35 crore, up from Rs 656.8 crore during the same period last year. Net profit for the half-year stood at Rs 28.01 crore, a turnaround from a loss of Rs 12.92 crore in the previous year.

Investor Outlook

Sai Life Sciences' IPO is expected to garner investor interest, given its robust business model, strong financial recovery, and strategic use of IPO proceeds for debt reduction. Additionally, the company's established presence in the CRDMO space and its partnerships with global pharmaceutical innovators add to its investment appeal.